Advertisement
News
Subscribe to MDT Magazine News

Spencer Pharmaceutical adds Buschmann to science board

December 28, 2010 8:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Spencer Pharmaceutical Inc., a metabolic disease-focused firm in Boston, has appointed Michael Buschmann, director of the FRSQ Group in Biomedical Science and Technology, to Spencer's scientific advisory board.

HeartWare seeks FDA nod for heart device

December 28, 2010 8:36 am | by Mass High Tech: The Journal of New England Technology | Comments

HeartWare International Inc. has submitted its Ventricular Assist System to the U.S. Food and Drug Administration for Pre-Market Approval (PMA) as a bridge to heart transplantation for patients with end-stage heart failure, the company reported today.

Allscripts Sunrise Electronic Health Record Receives ONC-ATCB 2011/2012 Certification as 'Complete EHR'

December 28, 2010 8:36 am | by Bio-Medicine.Org | Comments

CHICAGO, Dec. 28, 2010 /- Allscripts (Nasdaq: MDRX ) announced today that Sunrise Acute Care, Version 5.5 and Sunrise Emergency Care Version 5.5 are 2011/2012 CCHIT compliant and were certified as Complete EHRs on December 21, 2010 by the Certification Commission for Health Information...

TOPICS:
Advertisement

Accuray Incorporated's CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference

December 28, 2010 8:35 am | by Bio-Medicine.Org | Comments

SUNNYVALE, Calif., Dec. 28, 2010 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that its president and chief executive officer, Euan S. Thomson, Ph.D., is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in...

TOPICS:

ASU technology to treat chronic respiratory diseases

December 28, 2010 8:34 am | by Arizona State University | Comments

Miniature sensor technology developed at ASU's Biodesign Institute will be used to develop medical devices to better treat chronic respiratory diseases such as asthma.read more

TOPICS:

Purdue, NIST working on breathalyzers for medical diagnostics

December 28, 2010 8:33 am | by EurekAlert | Comments

(Purdue University) Researchers have overcome a fundamental obstacle in developing breath-analysis technology to rapidly diagnose patients by detecting chemical compounds called "biomarkers" in a person's respiration in real time.

TOPICS:

Tivorsan makes key DMD therapy development

December 28, 2010 7:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Tivorsan Pharmaceuticals, a protein therapeutics firm in Providence, R.I., has shown that mice with Duchenne Muscular Dystrophy have had improved muscle function due to biglycan protein, according to a news release today from the company.

Case Western Reserve receives $10M to study retinal disease, develop new treatments

December 28, 2010 6:40 am | by EurekAlert | Comments

(Case Western Reserve University) The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute to research and develop new treatments for diseases...

TOPICS:
Advertisement

Federal Register: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Devices; Third Party Review Program...(3)

December 28, 2010 6:39 am | by U.S. Food & Drug Administration | Comments

Section 210 of the FDAMA established section 523 of the FD&C Act (21 U.S.C. 360m), directing FDA to accredit persons in the private sector to review certain premarket notifications (510(k)s). Participation in this third-party review program by...

HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication

December 28, 2010 6:38 am | by Bio-Medicine.Org | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 28, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR ; ASX: HIN) today announced that it has submitted a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the HeartWare® Ventricular Assist System as a bridge...

TOPICS:

Medco Extends URAC Accreditation to Drug Therapy Management, PBM

December 28, 2010 6:38 am | by Bio-Medicine.Org | Comments

FRANKLIN LAKES, N.J., Dec. 28, 2010 /- Medco Health Solutions, Inc., (NYSE: MHS ) today announced that URAC, one of the nation's leading independent health care quality evaluators, has accredited Medco's Pharmacy Benefit Management and Drug Therapy Management (DTM) programs, recognizing...

TOPICS:

Federal Register: Request for Notification From Consumer Organizations Interested in Participating in the Selection Process for Nominations for Voting and/or NV Consumer Repre...

December 28, 2010 6:34 am | by U.S. Food & Drug Administration | Comments

The FDA is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing.

TOPICS:

Federal Register: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Devices; Third Party Review Program...

December 28, 2010 6:31 am | Comments

[Federal Register: December 28, 2010 (Volume 75, Number 248)] [Notices] [Page 81616-81617] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr28de10-116] ----------------------------------------------------------------------- DEPARTMENT O

Federal Register: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Devices; Third Party Review Program...(2)

December 28, 2010 6:31 am | by U.S. Food & Drug Administration | Comments

Section 210 of the FDAMA established section 523 of the FD&C Act (21 U.S.C. 360m), directing FDA to accredit persons in the private sector to review certain premarket notifications (510(k)s). Participation in this third-party review program by...

TOPICS:

FDA needs 4 more weeks for to review MannKind drug

December 28, 2010 2:45 am | by The Associated Press | Comments

MannKind Corp. said Tuesday the Food and Drug Administration will take an additional four weeks to review the application for the inhaled insulin Afrezza.The agency had initially expected to make a decision by Wednesday.MannKind had asked for approval of the product in March 2009, but the...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading